Overview

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant

Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients. This study will also evaluate the overall long-term impact of Advagraf on kidney and liver allograft recipients.
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Tacrolimus